CD33 and acute myeloid leukemia: For R/R CD33-positive AML, the single-arm phase II (MyloFrance 1) trial on 57 patients showed GO monotherapy resulted in a CR/CRp rate of 26% (95% confidence interval (CI) 16–40%) and the median relapse-free survival was 11.6 months [45].